Jialin Xia, Hong Chen, Xiaoxiao Wang, Weixuan Chen, Jun Lin, Feng Xu, Qixing Nie, Chuan Ye, Bitao Zhong, Min Zhao, Chuyu Yun, Guangyi Zeng, Yuejian Mao, Yongping Wen, Xuguang Zhang, Sen Yan, Xuemei Wang, Lulu Sun, Feng Liu, Chao Zhong, Pengyan Xia, Changtao Jiang, Huiying Rao, Yanli Pang
Non-alcoholic steatohepatitis (NASH) is a severe type of the non-alcoholic fatty liver disease (NAFLD). NASH is a growing global health concern due to its increasing morbidity, lack of well-defined biomarkers and lack of clinically effective treatments. Using metabolomic analysis, the most significantly changed active lipid sphingosine d18:1 [So(d18:1)] is selected from NASH patients. So(d18:1) inhibits macrophage HIF-2α as a direct inhibitor and promotes the inflammatory factors secretion. Male macrophage-specific HIF-2α knockout and overexpression mice verified the protective effect of HIF-2α on NASH progression...
June 4, 2024: Nature Communications